Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

MANSI RAMESH SHAH

Allopathic & Osteopathic Physicians Internal Medicine Hematology

NPI
1548689763
CMS profile
5701907
Location
NEW BRUNSWICK, NJ

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2025 · Entire year

$101,009.92

108 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2025 · entire year · sorted by reported total

By paying entity

PY2025 · entire year · sorted by reported total

Page 3 of 3; records 101–108 of 108 matching records. This page contains 8 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

MANSI RAMESH SHAH

NPI 1548689763 · CMS profile ID 5701907

Allopathic & Osteopathic Physicians / Internal Medicine / Hematology

NEW BRUNSWICK, NJ

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 3; records 101–108 of 108 matching records. This page contains 8 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1548689763?year=2025&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
MANSI RAMESH SHAH, NPI 1548689763, CMS profile ID 5701907. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–108 of 108 matching records. This page contains 8 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1548689763?year=2025&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
APA 7
IndustryPayments. (2026). MANSI RAMESH SHAH, NPI 1548689763, CMS profile ID 5701907. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–108 of 108 matching records. This page contains 8 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1548689763?year=2025&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
Bluebook
MANSI RAMESH SHAH, NPI 1548689763, CMS profile ID 5701907, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 3; records 101–108 of 108 matching records. This page contains 8 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1548689763?year=2025&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30

108 matching records · $101,009.92 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 108 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–108 of 108.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Janssen Biotech, Inc. $3,607.5002/26/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1175203507 CMS
Janssen Biotech, Inc. $113.9602/19/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1175203347 CMS
GENZYME CORPORATION $71.3802/05/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1233243697 CMS
Janssen Biotech, Inc. $3,575.0001/30/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1175203318 CMS
Janssen Biotech, Inc. $121.8501/27/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1175203712 CMS
Janssen Scientific Affairs, LLC $1,375.0001/14/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1174179947 CMS
Janssen Biotech, Inc. $26.5301/03/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1175202041 CMS
Janssen Biotech, Inc. $3,575.0001/03/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1175202864 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $44.61 3
PY2020 $95.00 1
PY2021 $212.96 2
PY2022 $113.96 1
PY2023 $5,401.01 8
PY2024 $24,167.98 30
PY2025 $101,009.92 108

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $8,835.52 23
PY2025 Principal investigator $841,205.23 185
PY2024 Recipient $827.34 4
PY2024 Principal investigator $238,289.40 43
PY2023 Recipient $4,488.54 22
PY2023 Principal investigator $232,853.43 26
PY2022 Recipient $847.25 1
PY2022 Principal investigator $253,965.39 14
PY2021 Principal investigator $33,932.60 1

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

208 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Janssen Research & Development, LLC $10,623.28 12/29/2025 Non-covered Recipient Entity
RUTGERS THE STATE UNIVERSITY
A Phase 3 Randomized Study Comparing Talquetamab SC in Combination WithDaratumumab SC and Pomalidomide (Tal-DP) or Talquetamab SC in Combination WithDaratumumab SC (Tal-D) Versus Daratumumab SC, Pomalidomide and Dexamethasone(DPd), in Participants With Relapsed or Refractory Multiple Myeloma who Have Receivedat Least 1 Prior Line of Therapy No dispute reported 06/30/2026 1175339853
Principal investigator 1 Janssen Research & Development, LLC $3,018.60 12/29/2025 Non-covered Recipient Entity
RUTGERS THE STATE UNIVERSITY
A Phase 2 Multicohort Open Label Study of JNJ68284528 a Chimeric Antigen Receptor T cell CART Therapy Directed Against BCMA in Subjects with Multiple Myeloma No dispute reported 06/30/2026 1175340310
Principal investigator 1 Janssen Research & Development, LLC $2,422.88 12/29/2025 Non-covered Recipient Entity
RUTGERS THE STATE UNIVERSITY
A Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Treatment in Participants With Newly Diagnosed Multiple Myeloma Who Are Minimal Residual Disease Positive After Frontline Autologous Stem Cell Transplant No dispute reported 06/30/2026 1175340549
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,608.70 12/24/2025 Non-covered Recipient Entity
RUTGERS THE STATE UNIVERSITY
PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA No dispute reported 06/30/2026 1184280204
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $5,103.40 12/24/2025 Non-covered Recipient Entity
RUTGERS THE STATE UNIVERSITY
PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA No dispute reported 06/30/2026 1184280206
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,218.25 12/24/2025 Non-covered Recipient Entity
RUTGERS THE STATE UNIVERSITY
PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA No dispute reported 06/30/2026 1184280208
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,872.20 12/24/2025 Non-covered Recipient Entity
RUTGERS THE STATE UNIVERSITY
PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA No dispute reported 06/30/2026 1184280210
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,705.35 12/24/2025 Non-covered Recipient Entity
RUTGERS THE STATE UNIVERSITY
PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA No dispute reported 06/30/2026 1184280212
Principal investigator 1 Janssen Research & Development, LLC $180.00 12/22/2025 Non-covered Recipient Entity
RUTGERS THE STATE UNIVERSITY
A Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Treatment in Participants With Newly Diagnosed Multiple Myeloma Who Are Minimal Residual Disease Positive After Frontline Autologous Stem Cell Transplant No dispute reported 06/30/2026 1175340036
Principal investigator 1 Janssen Research & Development, LLC $19,267.92 12/18/2025 Non-covered Recipient Entity
RUTGERS THE STATE UNIVERSITY
A Phase 2 Multicohort Open Label Study of JNJ68284528 a Chimeric Antigen Receptor T cell CART Therapy Directed Against BCMA in Subjects with Multiple Myeloma No dispute reported 06/30/2026 1175340223
Principal investigator 1 Janssen Research & Development, LLC $5,797.67 12/18/2025 Non-covered Recipient Entity
RUTGERS THE STATE UNIVERSITY
A Phase 3 Randomized Study Comparing Talquetamab SC in Combination WithDaratumumab SC and Pomalidomide (Tal-DP) or Talquetamab SC in Combination WithDaratumumab SC (Tal-D) Versus Daratumumab SC, Pomalidomide and Dexamethasone(DPd), in Participants With Relapsed or Refractory Multiple Myeloma who Have Receivedat Least 1 Prior Line of Therapy No dispute reported 06/30/2026 1175340276
Principal investigator 1 Janssen Research & Development, LLC $25,035.46 12/15/2025 Non-covered Recipient Entity
RUTGERS THE STATE UNIVERSITY
A Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Treatment in Participants With Newly Diagnosed Multiple Myeloma Who Are Minimal Residual Disease Positive After Frontline Autologous Stem Cell Transplant No dispute reported 06/30/2026 1175339989
Principal investigator 1 Janssen Research & Development, LLC $6,770.10 12/15/2025 Non-covered Recipient Entity
RUTGERS THE STATE UNIVERSITY
A Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Treatment in Participants With Newly Diagnosed Multiple Myeloma Who Are Minimal Residual Disease Positive After Frontline Autologous Stem Cell Transplant No dispute reported 06/30/2026 1175340303
Principal investigator 1 Janssen Research & Development, LLC $16,309.92 12/15/2025 Non-covered Recipient Entity
RUTGERS THE STATE UNIVERSITY
A Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Treatment in Participants With Newly Diagnosed Multiple Myeloma Who Are Minimal Residual Disease Positive After Frontline Autologous Stem Cell Transplant No dispute reported 06/30/2026 1175340524
Recipient Regeneron Pharmaceuticals, Inc. $1,259.44 12/07/2025 Covered Recipient Physician PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA No dispute reported 06/30/2026 1184122439
Principal investigator 1 ABBVIE INC. $18,498.10 12/04/2025 Non-covered Recipient Entity
RUTGERS THE STATE UNIVERSITY
Study of Intravenously (IV) Infused Etentamig in Combination With an Oral Cereblon E3 Ligase Modulatory Drug (CELMoD) Agent Assessing Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma No dispute reported 06/30/2026 1202528848
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,763.55 11/27/2025 Non-covered Recipient Entity
RUTGERS THE STATE UNIVERSITY
PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA No dispute reported 06/30/2026 1184265903
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,711.30 11/27/2025 Non-covered Recipient Entity
RUTGERS THE STATE UNIVERSITY
PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA No dispute reported 06/30/2026 1184265905
Principal investigator 1 ABBVIE INC. $21,573.50 11/20/2025 Non-covered Recipient Entity
RUTGERS THE STATE UNIVERSITY
Study of Intravenously (IV) Infused Etentamig in Combination With an Oral Cereblon E3 Ligase Modulatory Drug (CELMoD) Agent Assessing Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma No dispute reported 06/30/2026 1202524800
Principal investigator 1 Janssen Research & Development, LLC $18,103.99 11/17/2025 Non-covered Recipient Entity
RUTGERS THE STATE UNIVERSITY
A Phase 3 Randomized Study Comparing Talquetamab SC in Combination WithDaratumumab SC and Pomalidomide (Tal-DP) or Talquetamab SC in Combination WithDaratumumab SC (Tal-D) Versus Daratumumab SC, Pomalidomide and Dexamethasone(DPd), in Participants With Relapsed or Refractory Multiple Myeloma who Have Receivedat Least 1 Prior Line of Therapy No dispute reported 06/30/2026 1175340006
Principal investigator 1 Janssen Research & Development, LLC $1,970.00 11/17/2025 Non-covered Recipient Entity
RUTGERS THE STATE UNIVERSITY
A Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Treatment in Participants With Newly Diagnosed Multiple Myeloma Who Are Minimal Residual Disease Positive After Frontline Autologous Stem Cell Transplant No dispute reported 06/30/2026 1175340124
Principal investigator 1 Janssen Research & Development, LLC $15,293.10 11/10/2025 Non-covered Recipient Entity
RUTGERS THE STATE UNIVERSITY
A Phase 3 Randomized Study Comparing Talquetamab SC in Combination WithDaratumumab SC and Pomalidomide (Tal-DP) or Talquetamab SC in Combination WithDaratumumab SC (Tal-D) Versus Daratumumab SC, Pomalidomide and Dexamethasone(DPd), in Participants With Relapsed or Refractory Multiple Myeloma who Have Receivedat Least 1 Prior Line of Therapy No dispute reported 06/30/2026 1175339860
Principal investigator 1 Janssen Research & Development, LLC $391.30 11/07/2025 Non-covered Recipient Entity
RUTGERS THE STATE UNIVERSITY
A Phase 3 Study Comparing Daratumumab VELCADE bortezomib Lenalidomide and Dexamethasone DVRd with VELCADE Lenalidomide and Dexamethasone VRd in Subjects with Untreated Multiple Myeloma and for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy No dispute reported 06/30/2026 1175340510
Recipient Regeneron Pharmaceuticals, Inc. $1,826.20 11/06/2025 Covered Recipient Physician PHASE 1/2 FIH STUDY OF REGN5458 (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA No dispute reported 06/30/2026 1184122435
Recipient Regeneron Pharmaceuticals, Inc. $92.16 11/06/2025 Covered Recipient Physician PHASE 1/2 FIH STUDY OF REGN5458 (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA No dispute reported 06/30/2026 1184122437
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $124.45 10/31/2025 Non-covered Recipient Entity
RUTGERS THE STATE UNIVERSITY
PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA No dispute reported 06/30/2026 1184256697
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $124.45 10/31/2025 Non-covered Recipient Entity
RUTGERS THE STATE UNIVERSITY
PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA No dispute reported 06/30/2026 1184256699
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,711.30 10/31/2025 Non-covered Recipient Entity
RUTGERS THE STATE UNIVERSITY
PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA No dispute reported 06/30/2026 1184256701
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,472.85 10/31/2025 Non-covered Recipient Entity
RUTGERS THE STATE UNIVERSITY
PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA No dispute reported 06/30/2026 1184256703
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $9,702.70 10/30/2025 Non-covered Recipient Entity
RUTGERS THE STATE UNIVERSITY
PHASE 1/2 FIH STUDY OF REGN5458 (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA No dispute reported 06/30/2026 1184255699
Principal investigator 1 Janssen Research & Development, LLC $1,987.72 10/27/2025 Non-covered Recipient Entity
RUTGERS THE STATE UNIVERSITY
A Phase 3 Randomized Study Comparing Talquetamab SC in Combination WithDaratumumab SC and Pomalidomide (Tal-DP) or Talquetamab SC in Combination WithDaratumumab SC (Tal-D) Versus Daratumumab SC, Pomalidomide and Dexamethasone(DPd), in Participants With Relapsed or Refractory Multiple Myeloma who Have Receivedat Least 1 Prior Line of Therapy No dispute reported 06/30/2026 1175339881
Principal investigator 1 Janssen Research & Development, LLC $2,648.62 10/20/2025 Non-covered Recipient Entity
RUTGERS THE STATE UNIVERSITY
A Phase 2 Multicohort Open Label Study of JNJ68284528 a Chimeric Antigen Receptor T cell CART Therapy Directed Against BCMA in Subjects with Multiple Myeloma No dispute reported 06/30/2026 1175340352
Principal investigator 1 Janssen Research & Development, LLC $4,589.00 10/13/2025 Non-covered Recipient Entity
RUTGERS THE STATE UNIVERSITY
A Phase 2 Multicohort Open Label Study of JNJ68284528 a Chimeric Antigen Receptor T cell CART Therapy Directed Against BCMA in Subjects with Multiple Myeloma No dispute reported 06/30/2026 1175340151
Principal investigator 1 Janssen Research & Development, LLC $1,555.24 10/06/2025 Non-covered Recipient Entity
RUTGERS THE STATE UNIVERSITY
A Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Treatment in Participants With Newly Diagnosed Multiple Myeloma Who Are Minimal Residual Disease Positive After Frontline Autologous Stem Cell Transplant No dispute reported 06/30/2026 1175340089
Principal investigator 1 Janssen Research & Development, LLC $7,569.48 10/03/2025 Non-covered Recipient Entity
RUTGERS THE STATE UNIVERSITY
A Phase 3 Randomized Study Comparing Talquetamab SC in Combination WithDaratumumab SC and Pomalidomide (Tal-DP) or Talquetamab SC in Combination WithDaratumumab SC (Tal-D) Versus Daratumumab SC, Pomalidomide and Dexamethasone(DPd), in Participants With Relapsed or Refractory Multiple Myeloma who Have Receivedat Least 1 Prior Line of Therapy No dispute reported 06/30/2026 1175340260
Recipient Regeneron Pharmaceuticals, Inc. $390.92 10/03/2025 Covered Recipient Physician PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA No dispute reported 06/30/2026 1184122429
Recipient Regeneron Pharmaceuticals, Inc. $366.06 10/03/2025 Covered Recipient Physician PHASE 1/2 FIH STUDY OF REGN5458 (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA No dispute reported 06/30/2026 1184122431
Recipient Regeneron Pharmaceuticals, Inc. $256.64 10/03/2025 Covered Recipient Physician PHASE 1/2 FIH STUDY OF REGN5458 (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA No dispute reported 06/30/2026 1184122433
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,945.95 10/03/2025 Non-covered Recipient Entity
RUTGERS THE STATE UNIVERSITY
PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA No dispute reported 06/30/2026 1184246263
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,945.95 10/03/2025 Non-covered Recipient Entity
RUTGERS THE STATE UNIVERSITY
PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA No dispute reported 06/30/2026 1184246265
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,945.95 10/03/2025 Non-covered Recipient Entity
RUTGERS THE STATE UNIVERSITY
PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA No dispute reported 06/30/2026 1184246267
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,719.85 10/03/2025 Non-covered Recipient Entity
RUTGERS THE STATE UNIVERSITY
PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA No dispute reported 06/30/2026 1184246269
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,859.50 10/03/2025 Non-covered Recipient Entity
RUTGERS THE STATE UNIVERSITY
PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA No dispute reported 06/30/2026 1184246271
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,945.95 10/03/2025 Non-covered Recipient Entity
RUTGERS THE STATE UNIVERSITY
PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA No dispute reported 06/30/2026 1184246273
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,945.95 10/03/2025 Non-covered Recipient Entity
RUTGERS THE STATE UNIVERSITY
PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA No dispute reported 06/30/2026 1184246275
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,711.30 10/03/2025 Non-covered Recipient Entity
RUTGERS THE STATE UNIVERSITY
PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA No dispute reported 06/30/2026 1184246277
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $124.45 10/03/2025 Non-covered Recipient Entity
RUTGERS THE STATE UNIVERSITY
PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA No dispute reported 06/30/2026 1184246279
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $124.45 10/03/2025 Non-covered Recipient Entity
RUTGERS THE STATE UNIVERSITY
PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA No dispute reported 06/30/2026 1184246281
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,442.45 10/03/2025 Non-covered Recipient Entity
RUTGERS THE STATE UNIVERSITY
PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA No dispute reported 06/30/2026 1184246283
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,859.50 10/03/2025 Non-covered Recipient Entity
RUTGERS THE STATE UNIVERSITY
PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA No dispute reported 06/30/2026 1184246285
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,442.45 10/03/2025 Non-covered Recipient Entity
RUTGERS THE STATE UNIVERSITY
PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA No dispute reported 06/30/2026 1184246287
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,608.70 10/03/2025 Non-covered Recipient Entity
RUTGERS THE STATE UNIVERSITY
PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA No dispute reported 06/30/2026 1184246289
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,472.85 10/03/2025 Non-covered Recipient Entity
RUTGERS THE STATE UNIVERSITY
PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA No dispute reported 06/30/2026 1184246291
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,945.95 10/03/2025 Non-covered Recipient Entity
RUTGERS THE STATE UNIVERSITY
PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA No dispute reported 06/30/2026 1184246293
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,711.30 10/03/2025 Non-covered Recipient Entity
RUTGERS THE STATE UNIVERSITY
PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA No dispute reported 06/30/2026 1184246295
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,631.50 10/03/2025 Non-covered Recipient Entity
RUTGERS THE STATE UNIVERSITY
PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA No dispute reported 06/30/2026 1184246297
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,763.55 10/03/2025 Non-covered Recipient Entity
RUTGERS THE STATE UNIVERSITY
PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA No dispute reported 06/30/2026 1184246299
Recipient Regeneron Pharmaceuticals, Inc. $1,204.77 09/19/2025 Covered Recipient Physician PHASE 1/2 FIH STUDY OF REGN5458 (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA No dispute reported 06/30/2026 1184122421
Recipient Regeneron Pharmaceuticals, Inc. $263.89 09/19/2025 Covered Recipient Physician PHASE 1/2 FIH STUDY OF REGN5458 (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA No dispute reported 06/30/2026 1184122423
Recipient Regeneron Pharmaceuticals, Inc. $388.71 09/19/2025 Covered Recipient Physician PHASE 1/2 FIH STUDY OF REGN5458 (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA No dispute reported 06/30/2026 1184122425
Recipient Regeneron Pharmaceuticals, Inc. $152.24 09/19/2025 Covered Recipient Physician PHASE 1/2 FIH STUDY OF REGN5458 (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA No dispute reported 06/30/2026 1184122427
Principal investigator 1 Janssen Research & Development, LLC $4,239.62 09/04/2025 Non-covered Recipient Entity
RUTGERS THE STATE UNIVERSITY
A Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Treatment in Participants With Newly Diagnosed Multiple Myeloma Who Are Minimal Residual Disease Positive After Frontline Autologous Stem Cell Transplant No dispute reported 06/30/2026 1175340202
Principal investigator 1 Janssen Research & Development, LLC $391.30 09/04/2025 Non-covered Recipient Entity
RUTGERS THE STATE UNIVERSITY
A Phase 3 Study Comparing Daratumumab VELCADE bortezomib Lenalidomide and Dexamethasone DVRd with VELCADE Lenalidomide and Dexamethasone VRd in Subjects with Untreated Multiple Myeloma and for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy No dispute reported 06/30/2026 1175340397
Principal investigator 1 Janssen Research & Development, LLC $3,999.75 09/01/2025 Non-covered Recipient Entity
RUTGERS THE STATE UNIVERSITY
A Phase 3 Randomized Study Comparing Talquetamab SC in Combination WithDaratumumab SC and Pomalidomide (Tal-DP) or Talquetamab SC in Combination WithDaratumumab SC (Tal-D) Versus Daratumumab SC, Pomalidomide and Dexamethasone(DPd), in Participants With R No dispute reported 06/30/2026 1175339955
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,948.66 08/13/2025 Non-covered Recipient Entity
RUTGERS THE STATE UNIVERSITY
PHASE 1/2 FIH STUDY OF REGN5458 (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA No dispute reported 06/30/2026 1184226919
Principal investigator 1 Janssen Research & Development, LLC $3,851.00 07/31/2025 Non-covered Recipient Entity
RUTGERS THE STATE UNIVERSITY
A Phase 3 Randomized Study Comparing Talquetamab SC in Combination WithDaratumumab SC and Pomalidomide (Tal-DP) or Talquetamab SC in Combination WithDaratumumab SC (Tal-D) Versus Daratumumab SC, Pomalidomide and Dexamethasone(DPd), in Participants With R No dispute reported 06/30/2026 1175339823
Recipient Regeneron Pharmaceuticals, Inc. $74.32 07/29/2025 Covered Recipient Physician PHASE 1/2 FIH STUDY OF REGN5458 (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA No dispute reported 06/30/2026 1184122417
Recipient Regeneron Pharmaceuticals, Inc. $196.82 07/29/2025 Covered Recipient Physician PHASE 1/2 FIH STUDY OF REGN5458 (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA No dispute reported 06/30/2026 1184122419
Principal investigator 1 Janssen Research & Development, LLC $2,819.98 07/28/2025 Non-covered Recipient Entity
RUTGERS THE STATE UNIVERSITY
A Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Treatment in Participants With Newly Diagnosed Multiple Myeloma Who Are Minimal Residual Disease Positive After Frontline Autologous Stem Cell Transplant No dispute reported 06/30/2026 1175339758
Recipient Regeneron Pharmaceuticals, Inc. $310.68 07/09/2025 Covered Recipient Physician PHASE 1/2 FIH STUDY OF REGN5458 (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA No dispute reported 06/30/2026 1184122409
Recipient Regeneron Pharmaceuticals, Inc. $508.09 07/09/2025 Covered Recipient Physician PHASE 1/2 FIH STUDY OF REGN5458 (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA No dispute reported 06/30/2026 1184122411
Recipient Regeneron Pharmaceuticals, Inc. $121.27 07/09/2025 Covered Recipient Physician PHASE 1/2 FIH STUDY OF REGN5458 (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA No dispute reported 06/30/2026 1184122413
Recipient Regeneron Pharmaceuticals, Inc. $46.75 07/09/2025 Covered Recipient Physician PHASE 1/2 FIH STUDY OF REGN5458 (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA No dispute reported 06/30/2026 1184122415
Principal investigator 1 Janssen Research & Development, LLC $391.30 07/07/2025 Non-covered Recipient Entity
RUTGERS THE STATE UNIVERSITY
A Phase 3 Study Comparing Daratumumab VELCADE bortezomib Lenalidomide and Dexamethasone DVRd with VELCADE Lenalidomide and Dexamethasone VRd in Subjects with Untreated Multiple Myeloma and for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy No dispute reported 06/30/2026 1175340542
Principal investigator 1 Janssen Research & Development, LLC $9,109.18 06/30/2025 Non-covered Recipient Entity
RUTGERS THE STATE UNIVERSITY
A Phase 3 Randomized Study Comparing Talquetamab SC in Combination WithDaratumumab SC and Pomalidomide (Tal-DP) or Talquetamab SC in Combination WithDaratumumab SC (Tal-D) Versus Daratumumab SC, Pomalidomide and Dexamethasone(DPd), in Participants With R No dispute reported 06/30/2026 1175340450
Principal investigator 1 Janssen Research & Development, LLC $945.24 05/30/2025 Non-covered Recipient Entity
RUTGERS THE STATE UNIVERSITY
A Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Treatment in Participants With Newly Diagnosed Multiple Myeloma Who Are Minimal Residual Disease Positive After Frontline Autologous Stem Cell Transplant No dispute reported 06/30/2026 1175340016
Principal investigator 1 Janssen Research & Development, LLC $3,360.13 05/26/2025 Non-covered Recipient Entity
RUTGERS THE STATE UNIVERSITY
A Phase 3 Randomized Study Comparing Talquetamab SC in Combination WithDaratumumab SC and Pomalidomide (Tal-DP) or Talquetamab SC in Combination WithDaratumumab SC (Tal-D) Versus Daratumumab SC, Pomalidomide and Dexamethasone(DPd), in Participants With R No dispute reported 06/30/2026 1175339798
Principal investigator 1 Celgene Corporation $57,261.46 05/23/2025 Non-covered Recipient Entity
Rutgers The State University Of New Jersey Audit And Advisory Services
A Phase 2, Open-Label, Multicenter Study of Arlocabtagene Autoleucel (BMS-986393), a GPRC5D-directed CAR T Cell Therapy in Adult Participants with Relapsed or Refractory Multiple Myeloma (QUINTESSENTIAL) No dispute reported 06/30/2026 1222306719
Recipient Regeneron Pharmaceuticals, Inc. $304.53 05/15/2025 Covered Recipient Physician PHASE 1/2 FIH STUDY OF REGN5458 (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA No dispute reported 06/30/2026 1184122405
Recipient Regeneron Pharmaceuticals, Inc. $195.26 05/15/2025 Covered Recipient Physician PHASE 1/2 FIH STUDY OF REGN5458 (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA No dispute reported 06/30/2026 1184122407
Principal investigator 1 Janssen Research & Development, LLC $22,963.00 05/08/2025 Non-covered Recipient Entity
RUTGERS THE STATE UNIVERSITY
A Phase 3 Randomized Study Comparing Talquetamab SC in Combination WithDaratumumab SC and Pomalidomide (Tal-DP) or Talquetamab SC in Combination WithDaratumumab SC (Tal-D) Versus Daratumumab SC, Pomalidomide and Dexamethasone(DPd), in Participants With R No dispute reported 06/30/2026 1175340434
Principal investigator 1 Janssen Research & Development, LLC $10,195.76 05/02/2025 Non-covered Recipient Entity
RUTGERS THE STATE UNIVERSITY
A Phase 3 Randomized Study Comparing Talquetamab SC in Combination WithDaratumumab SC and Pomalidomide (Tal-DP) or Talquetamab SC in Combination WithDaratumumab SC (Tal-D) Versus Daratumumab SC, Pomalidomide and Dexamethasone(DPd), in Participants With R No dispute reported 06/30/2026 1175340143
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $7,204.34 04/30/2025 Non-covered Recipient Entity
RUTGERS THE STATE UNIVERSITY
PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA No dispute reported 06/30/2026 1184191185
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $8,710.00 04/30/2025 Non-covered Recipient Entity
RUTGERS THE STATE UNIVERSITY
PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA No dispute reported 06/30/2026 1184191187
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $7,204.34 04/30/2025 Non-covered Recipient Entity
RUTGERS THE STATE UNIVERSITY
PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA No dispute reported 06/30/2026 1184191189
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $8,710.00 04/30/2025 Non-covered Recipient Entity
RUTGERS THE STATE UNIVERSITY
PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA No dispute reported 06/30/2026 1184191191
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $7,204.34 04/30/2025 Non-covered Recipient Entity
RUTGERS THE STATE UNIVERSITY
PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA No dispute reported 06/30/2026 1184191193
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $7,204.34 04/30/2025 Non-covered Recipient Entity
RUTGERS THE STATE UNIVERSITY
PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA No dispute reported 06/30/2026 1184191197
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $7,204.34 04/30/2025 Non-covered Recipient Entity
RUTGERS THE STATE UNIVERSITY
PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA No dispute reported 06/30/2026 1184191199
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $8,710.00 04/30/2025 Non-covered Recipient Entity
RUTGERS THE STATE UNIVERSITY
PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA No dispute reported 06/30/2026 1184191201
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,021.20 04/30/2025 Non-covered Recipient Entity
RUTGERS THE STATE UNIVERSITY
PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA No dispute reported 06/30/2026 1184191203
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,074.50 04/30/2025 Non-covered Recipient Entity
RUTGERS THE STATE UNIVERSITY
PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA No dispute reported 06/30/2026 1184191205
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,072.50 04/30/2025 Non-covered Recipient Entity
RUTGERS THE STATE UNIVERSITY
PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA No dispute reported 06/30/2026 1184191207
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $650.00 04/30/2025 Non-covered Recipient Entity
RUTGERS THE STATE UNIVERSITY
PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA No dispute reported 06/30/2026 1184191209
Principal investigator 1 Janssen Research & Development, LLC $76,888.30 04/24/2025 Non-covered Recipient Entity
RUTGERS THE STATE UNIVERSITY
A Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Treatment in Participants With Newly Diagnosed Multiple Myeloma Who Are Minimal Residual Disease Positive After Frontline Autologous Stem Cell Transplant No dispute reported 06/30/2026 1175340030
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,038.10 04/23/2025 Non-covered Recipient Entity
RUTGERS THE STATE UNIVERSITY
PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA No dispute reported 06/30/2026 1184188161
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,308.50 04/23/2025 Non-covered Recipient Entity
RUTGERS THE STATE UNIVERSITY
PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA No dispute reported 06/30/2026 1184188163
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,550.75 04/23/2025 Non-covered Recipient Entity
RUTGERS THE STATE UNIVERSITY
PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA No dispute reported 06/30/2026 1184188165
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,308.50 04/23/2025 Non-covered Recipient Entity
RUTGERS THE STATE UNIVERSITY
PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA No dispute reported 06/30/2026 1184188167
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,081.80 04/23/2025 Non-covered Recipient Entity
RUTGERS THE STATE UNIVERSITY
PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA No dispute reported 06/30/2026 1184188169
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,036.80 04/23/2025 Non-covered Recipient Entity
RUTGERS THE STATE UNIVERSITY
PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA No dispute reported 06/30/2026 1184188171
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,309.80 04/23/2025 Non-covered Recipient Entity
RUTGERS THE STATE UNIVERSITY
PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA No dispute reported 06/30/2026 1184188173
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,308.50 04/23/2025 Non-covered Recipient Entity
RUTGERS THE STATE UNIVERSITY
PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA No dispute reported 06/30/2026 1184188175
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,550.75 04/23/2025 Non-covered Recipient Entity
RUTGERS THE STATE UNIVERSITY
PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA No dispute reported 06/30/2026 1184188177
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,308.50 04/23/2025 Non-covered Recipient Entity
RUTGERS THE STATE UNIVERSITY
PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA No dispute reported 06/30/2026 1184188179
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,308.50 04/23/2025 Non-covered Recipient Entity
RUTGERS THE STATE UNIVERSITY
PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA No dispute reported 06/30/2026 1184188181
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,308.50 04/23/2025 Non-covered Recipient Entity
RUTGERS THE STATE UNIVERSITY
PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA No dispute reported 06/30/2026 1184188183
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,308.50 04/23/2025 Non-covered Recipient Entity
RUTGERS THE STATE UNIVERSITY
PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA No dispute reported 06/30/2026 1184188185
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,036.80 04/23/2025 Non-covered Recipient Entity
RUTGERS THE STATE UNIVERSITY
PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA No dispute reported 06/30/2026 1184188187
Recipient Regeneron Pharmaceuticals, Inc. $82.29 04/14/2025 Covered Recipient Physician PHASE 1/2 FIH STUDY OF REGN5458 (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA No dispute reported 06/30/2026 1184122401
Recipient Regeneron Pharmaceuticals, Inc. $88.62 04/14/2025 Covered Recipient Physician PHASE 1/2 FIH STUDY OF REGN5458 (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA No dispute reported 06/30/2026 1184122403
Recipient Regeneron Pharmaceuticals, Inc. $412.60 04/10/2025 Covered Recipient Physician PHASE 1/2 FIH STUDY OF REGN5458 (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA No dispute reported 06/30/2026 1184122399
Recipient Regeneron Pharmaceuticals, Inc. $181.31 04/09/2025 Covered Recipient Physician PHASE 1/2 FIH STUDY OF REGN5458 (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA No dispute reported 06/30/2026 1184122397
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,606.50 04/04/2025 Non-covered Recipient Entity
RUTGERS THE STATE UNIVERSITY
PHASE 1/2 FIH STUDY OF REGN5458 (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA No dispute reported 06/30/2026 1184181666
Principal investigator 1 Janssen Research & Development, LLC $6,097.34 04/03/2025 Non-covered Recipient Entity
RUTGERS THE STATE UNIVERSITY
A Phase 3 Randomized Study Comparing Talquetamab SC in Combination WithDaratumumab SC and Pomalidomide (Tal-DP) or Talquetamab SC in Combination WithDaratumumab SC (Tal-D) Versus Daratumumab SC, Pomalidomide and Dexamethasone(DPd), in Participants With R No dispute reported 06/30/2026 1175340325
Principal investigator 1 Janssen Research & Development, LLC $877.50 03/03/2025 Non-covered Recipient Entity
RUTGERS THE STATE UNIVERSITY
A Phase 3 Study Comparing Daratumumab VELCADE bortezomib Lenalidomide and Dexamethasone DVRd with VELCADE Lenalidomide and Dexamethasone VRd in Subjects with Untreated Multiple Myeloma and for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy No dispute reported 06/30/2026 1175340427
Principal investigator 1 Janssen Research & Development, LLC $12,317.16 03/03/2025 Non-covered Recipient Entity
RUTGERS THE STATE UNIVERSITY
A Phase 3 Randomized Study Comparing Talquetamab SC in Combination WithDaratumumab SC and Pomalidomide (Tal-DP) or Talquetamab SC in Combination WithDaratumumab SC (Tal-D) Versus Daratumumab SC, Pomalidomide and Dexamethasone(DPd), in Participants With R No dispute reported 06/30/2026 1175340482
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,096.65 02/12/2025 Non-covered Recipient Entity
RUTGERS THE STATE UNIVERSITY
PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA No dispute reported 06/30/2026 1184153676
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,820.55 02/12/2025 Non-covered Recipient Entity
RUTGERS THE STATE UNIVERSITY
PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA No dispute reported 06/30/2026 1184153678
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,769.95 02/12/2025 Non-covered Recipient Entity
RUTGERS THE STATE UNIVERSITY
PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA No dispute reported 06/30/2026 1184153680
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,085.00 02/12/2025 Non-covered Recipient Entity
RUTGERS THE STATE UNIVERSITY
PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA No dispute reported 06/30/2026 1184153682
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,170.75 02/12/2025 Non-covered Recipient Entity
RUTGERS THE STATE UNIVERSITY
PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA No dispute reported 06/30/2026 1184153684
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,619.15 02/12/2025 Non-covered Recipient Entity
RUTGERS THE STATE UNIVERSITY
PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA No dispute reported 06/30/2026 1184153686
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,036.80 02/12/2025 Non-covered Recipient Entity
RUTGERS THE STATE UNIVERSITY
PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA No dispute reported 06/30/2026 1184153688
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,498.50 02/12/2025 Non-covered Recipient Entity
RUTGERS THE STATE UNIVERSITY
PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA No dispute reported 06/30/2026 1184153690
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,600.50 02/12/2025 Non-covered Recipient Entity
RUTGERS THE STATE UNIVERSITY
PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA No dispute reported 06/30/2026 1184153692
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,096.65 02/12/2025 Non-covered Recipient Entity
RUTGERS THE STATE UNIVERSITY
PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA No dispute reported 06/30/2026 1184153694
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,674.25 02/12/2025 Non-covered Recipient Entity
RUTGERS THE STATE UNIVERSITY
PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA No dispute reported 06/30/2026 1184153696
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,085.00 02/12/2025 Non-covered Recipient Entity
RUTGERS THE STATE UNIVERSITY
PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA No dispute reported 06/30/2026 1184153698
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,769.95 02/12/2025 Non-covered Recipient Entity
RUTGERS THE STATE UNIVERSITY
PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA No dispute reported 06/30/2026 1184153700
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,820.55 02/12/2025 Non-covered Recipient Entity
RUTGERS THE STATE UNIVERSITY
PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA No dispute reported 06/30/2026 1184153702
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,096.65 02/12/2025 Non-covered Recipient Entity
RUTGERS THE STATE UNIVERSITY
PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA No dispute reported 06/30/2026 1184153704
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,946.55 02/12/2025 Non-covered Recipient Entity
RUTGERS THE STATE UNIVERSITY
PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA No dispute reported 06/30/2026 1184153706
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,161.60 02/12/2025 Non-covered Recipient Entity
RUTGERS THE STATE UNIVERSITY
PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA No dispute reported 06/30/2026 1184153708
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,560.60 02/12/2025 Non-covered Recipient Entity
RUTGERS THE STATE UNIVERSITY
PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA No dispute reported 06/30/2026 1184153710
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,238.20 02/12/2025 Non-covered Recipient Entity
RUTGERS THE STATE UNIVERSITY
PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA No dispute reported 06/30/2026 1184153712
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,036.80 02/12/2025 Non-covered Recipient Entity
RUTGERS THE STATE UNIVERSITY
PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA No dispute reported 06/30/2026 1184153714
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,279.05 02/12/2025 Non-covered Recipient Entity
RUTGERS THE STATE UNIVERSITY
PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA No dispute reported 06/30/2026 1184153716
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,036.80 02/12/2025 Non-covered Recipient Entity
RUTGERS THE STATE UNIVERSITY
PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA No dispute reported 06/30/2026 1184153718
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,085.00 02/12/2025 Non-covered Recipient Entity
RUTGERS THE STATE UNIVERSITY
PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA No dispute reported 06/30/2026 1184153720
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,769.95 02/12/2025 Non-covered Recipient Entity
RUTGERS THE STATE UNIVERSITY
PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA No dispute reported 06/30/2026 1184153722
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,820.55 02/12/2025 Non-covered Recipient Entity
RUTGERS THE STATE UNIVERSITY
PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA No dispute reported 06/30/2026 1184153724
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,096.65 02/12/2025 Non-covered Recipient Entity
RUTGERS THE STATE UNIVERSITY
PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA No dispute reported 06/30/2026 1184153726
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,946.55 02/12/2025 Non-covered Recipient Entity
RUTGERS THE STATE UNIVERSITY
PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA No dispute reported 06/30/2026 1184153728
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,161.60 02/12/2025 Non-covered Recipient Entity
RUTGERS THE STATE UNIVERSITY
PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA No dispute reported 06/30/2026 1184153730
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,560.60 02/12/2025 Non-covered Recipient Entity
RUTGERS THE STATE UNIVERSITY
PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA No dispute reported 06/30/2026 1184153732
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,038.10 02/12/2025 Non-covered Recipient Entity
RUTGERS THE STATE UNIVERSITY
PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA No dispute reported 06/30/2026 1184153734
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,036.80 02/12/2025 Non-covered Recipient Entity
RUTGERS THE STATE UNIVERSITY
PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA No dispute reported 06/30/2026 1184153736
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,036.80 02/12/2025 Non-covered Recipient Entity
RUTGERS THE STATE UNIVERSITY
PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA No dispute reported 06/30/2026 1184153738
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,036.80 02/12/2025 Non-covered Recipient Entity
RUTGERS THE STATE UNIVERSITY
PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA No dispute reported 06/30/2026 1184153740
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,081.80 02/12/2025 Non-covered Recipient Entity
RUTGERS THE STATE UNIVERSITY
PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA No dispute reported 06/30/2026 1184153742
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,619.15 02/12/2025 Non-covered Recipient Entity
RUTGERS THE STATE UNIVERSITY
PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA No dispute reported 06/30/2026 1184153744
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,036.80 02/12/2025 Non-covered Recipient Entity
RUTGERS THE STATE UNIVERSITY
PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA No dispute reported 06/30/2026 1184153746
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,036.80 02/12/2025 Non-covered Recipient Entity
RUTGERS THE STATE UNIVERSITY
PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA No dispute reported 06/30/2026 1184153748
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,498.50 02/12/2025 Non-covered Recipient Entity
RUTGERS THE STATE UNIVERSITY
PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA No dispute reported 06/30/2026 1184153750
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,096.65 02/12/2025 Non-covered Recipient Entity
RUTGERS THE STATE UNIVERSITY
PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA No dispute reported 06/30/2026 1184153752
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,600.50 02/12/2025 Non-covered Recipient Entity
RUTGERS THE STATE UNIVERSITY
PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA No dispute reported 06/30/2026 1184153754
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,769.95 02/12/2025 Non-covered Recipient Entity
RUTGERS THE STATE UNIVERSITY
PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA No dispute reported 06/30/2026 1184153756
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,085.00 02/12/2025 Non-covered Recipient Entity
RUTGERS THE STATE UNIVERSITY
PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA No dispute reported 06/30/2026 1184153758
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,619.15 02/12/2025 Non-covered Recipient Entity
RUTGERS THE STATE UNIVERSITY
PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA No dispute reported 06/30/2026 1184153760
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,498.50 02/12/2025 Non-covered Recipient Entity
RUTGERS THE STATE UNIVERSITY
PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA No dispute reported 06/30/2026 1184153762
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,096.65 02/12/2025 Non-covered Recipient Entity
RUTGERS THE STATE UNIVERSITY
PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA No dispute reported 06/30/2026 1184153764
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,600.50 02/12/2025 Non-covered Recipient Entity
RUTGERS THE STATE UNIVERSITY
PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA No dispute reported 06/30/2026 1184153766
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,238.20 02/12/2025 Non-covered Recipient Entity
RUTGERS THE STATE UNIVERSITY
PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA No dispute reported 06/30/2026 1184153768
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,560.60 02/12/2025 Non-covered Recipient Entity
RUTGERS THE STATE UNIVERSITY
PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA No dispute reported 06/30/2026 1184153770
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,161.60 02/12/2025 Non-covered Recipient Entity
RUTGERS THE STATE UNIVERSITY
PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA No dispute reported 06/30/2026 1184153772
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,946.55 02/12/2025 Non-covered Recipient Entity
RUTGERS THE STATE UNIVERSITY
PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA No dispute reported 06/30/2026 1184153774
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,096.65 02/12/2025 Non-covered Recipient Entity
RUTGERS THE STATE UNIVERSITY
PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA No dispute reported 06/30/2026 1184153776
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,820.55 02/12/2025 Non-covered Recipient Entity
RUTGERS THE STATE UNIVERSITY
PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA No dispute reported 06/30/2026 1184153778
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,238.20 02/12/2025 Non-covered Recipient Entity
RUTGERS THE STATE UNIVERSITY
PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA No dispute reported 06/30/2026 1184153780
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,085.00 02/12/2025 Non-covered Recipient Entity
RUTGERS THE STATE UNIVERSITY
PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA No dispute reported 06/30/2026 1184153782
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,036.80 02/12/2025 Non-covered Recipient Entity
RUTGERS THE STATE UNIVERSITY
PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA No dispute reported 06/30/2026 1184153784
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,036.80 02/12/2025 Non-covered Recipient Entity
RUTGERS THE STATE UNIVERSITY
PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA No dispute reported 06/30/2026 1184153786
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,081.80 02/12/2025 Non-covered Recipient Entity
RUTGERS THE STATE UNIVERSITY
PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA No dispute reported 06/30/2026 1184153788
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,619.15 02/12/2025 Non-covered Recipient Entity
RUTGERS THE STATE UNIVERSITY
PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA No dispute reported 06/30/2026 1184153790
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,036.80 02/12/2025 Non-covered Recipient Entity
RUTGERS THE STATE UNIVERSITY
PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA No dispute reported 06/30/2026 1184153792
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,036.80 02/12/2025 Non-covered Recipient Entity
RUTGERS THE STATE UNIVERSITY
PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA No dispute reported 06/30/2026 1184153794
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,498.50 02/12/2025 Non-covered Recipient Entity
RUTGERS THE STATE UNIVERSITY
PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA No dispute reported 06/30/2026 1184153796
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,096.65 02/12/2025 Non-covered Recipient Entity
RUTGERS THE STATE UNIVERSITY
PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA No dispute reported 06/30/2026 1184153798
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,600.50 02/12/2025 Non-covered Recipient Entity
RUTGERS THE STATE UNIVERSITY
PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA No dispute reported 06/30/2026 1184153800
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,619.15 02/12/2025 Non-covered Recipient Entity
RUTGERS THE STATE UNIVERSITY
PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA No dispute reported 06/30/2026 1184153802
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,674.25 02/12/2025 Non-covered Recipient Entity
RUTGERS THE STATE UNIVERSITY
PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA No dispute reported 06/30/2026 1184153804
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,170.75 02/12/2025 Non-covered Recipient Entity
RUTGERS THE STATE UNIVERSITY
PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA No dispute reported 06/30/2026 1184153806
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,170.75 02/12/2025 Non-covered Recipient Entity
RUTGERS THE STATE UNIVERSITY
PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA No dispute reported 06/30/2026 1184153808
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,036.80 02/12/2025 Non-covered Recipient Entity
RUTGERS THE STATE UNIVERSITY
PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA No dispute reported 06/30/2026 1184153810
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,279.05 02/12/2025 Non-covered Recipient Entity
RUTGERS THE STATE UNIVERSITY
PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA No dispute reported 06/30/2026 1184153812
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,036.80 02/12/2025 Non-covered Recipient Entity
RUTGERS THE STATE UNIVERSITY
PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA No dispute reported 06/30/2026 1184153814
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,038.10 02/12/2025 Non-covered Recipient Entity
RUTGERS THE STATE UNIVERSITY
PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA No dispute reported 06/30/2026 1184153816
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,036.80 02/12/2025 Non-covered Recipient Entity
RUTGERS THE STATE UNIVERSITY
PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA No dispute reported 06/30/2026 1184153818
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,036.80 02/12/2025 Non-covered Recipient Entity
RUTGERS THE STATE UNIVERSITY
PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA No dispute reported 06/30/2026 1184153820
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,081.80 02/12/2025 Non-covered Recipient Entity
RUTGERS THE STATE UNIVERSITY
PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA No dispute reported 06/30/2026 1184153822
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,560.60 02/12/2025 Non-covered Recipient Entity
RUTGERS THE STATE UNIVERSITY
PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA No dispute reported 06/30/2026 1184153824
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,036.80 02/12/2025 Non-covered Recipient Entity
RUTGERS THE STATE UNIVERSITY
PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA No dispute reported 06/30/2026 1184153826
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,498.50 02/12/2025 Non-covered Recipient Entity
RUTGERS THE STATE UNIVERSITY
PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA No dispute reported 06/30/2026 1184153828
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,096.65 02/12/2025 Non-covered Recipient Entity
RUTGERS THE STATE UNIVERSITY
PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA No dispute reported 06/30/2026 1184153830
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,600.50 02/12/2025 Non-covered Recipient Entity
RUTGERS THE STATE UNIVERSITY
PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA No dispute reported 06/30/2026 1184153832
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,238.20 02/12/2025 Non-covered Recipient Entity
RUTGERS THE STATE UNIVERSITY
PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA No dispute reported 06/30/2026 1184153834
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,560.60 02/12/2025 Non-covered Recipient Entity
RUTGERS THE STATE UNIVERSITY
PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA No dispute reported 06/30/2026 1184153836
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,946.55 02/12/2025 Non-covered Recipient Entity
RUTGERS THE STATE UNIVERSITY
PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA No dispute reported 06/30/2026 1184153838
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,096.65 02/12/2025 Non-covered Recipient Entity
RUTGERS THE STATE UNIVERSITY
PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA No dispute reported 06/30/2026 1184153840
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,820.55 02/12/2025 Non-covered Recipient Entity
RUTGERS THE STATE UNIVERSITY
PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA No dispute reported 06/30/2026 1184153842
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,769.95 02/12/2025 Non-covered Recipient Entity
RUTGERS THE STATE UNIVERSITY
PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA No dispute reported 06/30/2026 1184153844
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,238.20 02/12/2025 Non-covered Recipient Entity
RUTGERS THE STATE UNIVERSITY
PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA No dispute reported 06/30/2026 1184153846
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,674.25 02/12/2025 Non-covered Recipient Entity
RUTGERS THE STATE UNIVERSITY
PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA No dispute reported 06/30/2026 1184153848
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,161.60 02/12/2025 Non-covered Recipient Entity
RUTGERS THE STATE UNIVERSITY
PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA No dispute reported 06/30/2026 1184153850
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,946.55 02/12/2025 Non-covered Recipient Entity
RUTGERS THE STATE UNIVERSITY
PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA No dispute reported 06/30/2026 1184153852
Recipient Regeneron Pharmaceuticals, Inc. $111.95 02/07/2025 Covered Recipient Physician PHASE 1/2 FIH STUDY OF REGN5458 (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA No dispute reported 06/30/2026 1184122395
Principal investigator 1 Janssen Research & Development, LLC $1,987.72 01/24/2025 Non-covered Recipient Entity
RUTGERS THE STATE UNIVERSITY
A Phase 3 Randomized Study Comparing Talquetamab SC in Combination WithDaratumumab SC and Pomalidomide (Tal-DP) or Talquetamab SC in Combination WithDaratumumab SC (Tal-D) Versus Daratumumab SC, Pomalidomide and Dexamethasone(DPd), in Participants With R No dispute reported 06/30/2026 1175339749